PR Newswire Clinical TrialsOriginal article
Vincere Biosciences Awarded $2.7 Million NIH Grant to Advance USP30 Inhibitor for Acute Kidney Injury
USP30 inhibitorPositive
AI Analysis
Summary
Vincere Biosciences received a $2.7 million SBIR Phase II grant from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases to support IND-enabling development of its USP30 inhibitor small molecule for acute kidney injury treatment.
Outcome Details
SBIR Phase II grant award
Importance:4/10
Sentiment:
0.60
grantNIHSBIRUSP30 inhibitoracute kidney injurymitochondrial dysfunction
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 10, 2026 11:53 AM